# Darmiyan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/darmiyan

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.darmiyan.com
- Total disclosed funding: $10M
- Latest round: Seed (Mar 31, 2020)
- Investors on record: 11

## About

Darmiyan, Inc. develops advanced medical imaging technology focused on enhancing brain health, particularly through early detection of neurodegenerative diseases using innovative software solutions.Founded in 2016 in San Francisco, US, Darmiyan, Inc. specializes in medical imaging technology aimed at evaluating brain health. The company's founder, Thomas Liebmann, and CEO, Padideh Kamali-Zare, have been pivotal in guiding its mission. Darmiyan has completed two deals, with the most recent being a Seed round of funding in March 2020 where the company raised USD 6.43 mn led by Eisai, alongside investors IT-Farm and Y Combinator. The company has raised a total of USD 3.536 mn to date.Darmiyan specializes in advanced medical imaging technology aimed at improving brain health, particularly in the early detection of neurodegenerative diseases. Their flagship product, BrainSee, is an FDA-approved software designed to evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). By combining brain MRI data with cognitive test scores, BrainSee generates a score that assesses the likelihood of progression to Alzheimer’s dementia. This innovative product serves healthcare providers, including neurologists and geriatricians, by providing critical insights into patient health and aiding in treatment planning. Additionally, Darmiyan's technology is employed in various global markets, enhancing brain health diagnostics and monitoring capabilities across North America, Europe, and parts of Asia.Darmiyan’s revenue model is based on the provision of their proprietary BrainSee software, which is utilized by healthcare professionals to assess cognitive decline in patients. Revenue is generated primarily through direct sales of the software to medical facilities and clinics, as well as potential partnerships with pharmaceutical companies for research and development purposes. The software is typically offered under a subscription model that allows facilities to access ongoing updates and support. This structure ensures that medical practitioners can effectively use BrainSee in conjunction with their existing diagnostic tools. The company is also exploring avenues for expanding its product offerings to include additional tests tailored for various neurological conditions, further enhancing its revenue potential within the healthcare sector.In March 2020, Darmiyan, Inc. raised USD 6.43 mn in Seed funding led by Eisai, with participation from IT-Farm and Y Combinator. The funds are expected to support the design and launch of new products aimed at expanding its medical imaging portfolio, specifically targeting additional neurological assessments. Darmiyan plans to penetrate new markets in Europe and Asia by 2023, enhancing its global footprint. The funding will be utilized to boost product development and facilitate entry into these new regions.

## Funding rounds

- Seed, Mar 31, 2020, $6.4M — IT-Farm Corporation, Y Combinator, Eisai
- Seed, Oct 1, 2017, $3.7M — IT-Farm Corporation, Pegasus Tech Ventures, DHVC, Soma Capital Management, AAF Management, Seven Seas Partners, UpHonest Capital, Hanmi Pharmaceutical Co., Ltd., Arkitekt Ventures

## Investors

- IT-Farm Corporation (https://capitalatlas.ai/funds/it-farm-corporation) — Seed
- Pegasus Tech Ventures (https://capitalatlas.ai/funds/pegasus-tech-ventures) — Seed
- DHVC (https://capitalatlas.ai/funds/dhvc) — Seed
- Soma Capital Management (https://capitalatlas.ai/funds/soma-capital-management) — Seed
- AAF Management (https://capitalatlas.ai/funds/aaf-management) — Seed
- Seven Seas Partners (https://capitalatlas.ai/funds/seven-seas-partners) — Seed
- UpHonest Capital (https://capitalatlas.ai/funds/uphonest-capital) — Seed
- Hanmi Pharmaceutical Co., Ltd. — Seed
- Arkitekt Ventures (https://capitalatlas.ai/funds/arkitekt-ventures) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Eisai — Seed